LondonCamizestrant failed as a first-line breast cancer therapy.

The pill won’t replace fulvestrant’s monthly injection for most newly diagnosed patients.

It degrades the estrogen receptor by pill rather than shot, but SERENA-4 found it no better than standard care upfront.

AstraZeneca’s drug stays approved only for patients with a resistance mutation caught by blood test.

How each outlet framed it
STAT
notes drug already gained accelerated approval for resistance-cases despite failing larger first-line pivotal trial

Sources: STAT